Scott's Liquid Gold-Inc. (SLGD)’s Insider, Iszo Capital Lp Paid for 53323 shares of the Company; Diffusion Pharmaceuticals (DFFN) Sellers Decreased By 2.94% Their Shorts

Diffusion Pharmaceuticals Incorporated (NASDAQ:DFFN) had a decrease of 2.94% in short interest. DFFN’s SI was 530,600 shares in February as released by FINRA. Its down 2.94% from 546,700 shares previously. With 176,000 avg volume, 3 days are for Diffusion Pharmaceuticals Incorporated (NASDAQ:DFFN)’s short sellers to cover DFFN’s short positions. The SI to Diffusion Pharmaceuticals Incorporated’s float is 7.84%. The stock decreased 0.91% or $0.0059 during the last trading session, reaching $0.6446. About 372,191 shares traded. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has declined 76.39% since February 9, 2017 and is downtrending. It has underperformed by 93.09% the S&P500.

The Scotts Liquid Gold Inc’s insider Iszo Capital Lp obtained – 53,323 shares of Scotts Liquid Gold Inc, based on the avg. market share price of $3.2 for a share. These shares recently had a value of nearly $172,139 U.S Dollars. Iszo Capital Lp right now has in hand 1.28 million shares which make up about 10.75% of the Colorado-based company’s market cap.

Scott's Liquid Gold-Inc., through its subsidiaries, develops, makes, markets, and sells household products, and skin and hair care products in the United States and internationally. The company has market cap of $39.22 million. The company's household products include Scott's Liquid Gold wood care, floor restore, and wood wash products; Dust 'N Go wipes; and Touch of Scent air fresheners. It has a 9.43 P/E ratio. The Company’s skin and hair care products comprise Alpha Skin Care products, such as facial care products, body lotion, body wash, and foot cream; Prell shampoos; Denorex and Zincon shampoos and conditioners; and Neoteric diabetic healing cream to address the skin conditions of persons living with diabetes.

The stock increased 1.85% or $0.06 during the last trading session, reaching $3.3. About shares traded. Scott's Liquid Gold-Inc. (OTCMKTS:SLGD) has 0.00% since February 9, 2017 and is . It has underperformed by 16.70% the S&P500.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The company has market cap of $32.23 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. It currently has negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.